- Clinical Trials
- March 2025
- 490 Pages
Global
From €3140EUR$3,450USD£2,667GBP
- Report
- February 2025
- 52 Pages
Global
From €6826EUR$7,500USD£5,798GBP
- Report
- December 2024
Global
From €6826EUR$7,500USD£5,798GBP
- Report
- December 2024
Global
From €6826EUR$7,500USD£5,798GBP
- Newsletter
- April 2025
- 88 Pages
Global
€1200EUR$1,318USD£1,019GBP
- Report
- February 2025
- 135 Pages
Global
From €3973EUR$4,365USD£3,374GBP
€4414EUR$4,850USD£3,749GBP
- Report
- October 2024
- 90 Pages
Asia Pacific
From €4505EUR$4,950USD£3,827GBP
- Report
- August 2024
- 130 Pages
North America
From €3641EUR$4,000USD£3,092GBP
- Report
- November 2024
- 80 Pages
North America
From €3140EUR$3,450USD£2,667GBP
- Report
- November 2024
- 92 Pages
Africa, Middle East
From €3140EUR$3,450USD£2,667GBP
- Report
- November 2024
- 87 Pages
Europe
From €3140EUR$3,450USD£2,667GBP
- Report
- November 2024
- 89 Pages
Asia Pacific
From €3140EUR$3,450USD£2,667GBP
- Report
- June 2023
- 289 Pages
Global
From €4813EUR$5,474USD£3,950GBP
- Report
- June 2022
- 124 Pages
Global
From €5006EUR$5,500USD£4,252GBP
- Report
- April 2018
- 97 Pages
Global
From €14563EUR$16,000USD£12,369GBP
- Report
- December 2022
- 153 Pages
Global
From €2389EUR$2,625USD£2,029GBP
€4778EUR$5,250USD£4,059GBP
- Report
- November 2022
- 286 Pages
Global
From €2389EUR$2,625USD£2,029GBP
€4778EUR$5,250USD£4,059GBP
- Report
- June 2022
- 257 Pages
Global
From €2389EUR$2,625USD£2,029GBP
€4778EUR$5,250USD£4,059GBP
- Report
- June 2022
- 177 Pages
Global
From €2389EUR$2,625USD£2,029GBP
€4778EUR$5,250USD£4,059GBP
- Report
- May 2022
- 170 Pages
Middle East
From €2389EUR$2,625USD£2,029GBP
€4778EUR$5,250USD£4,059GBP

Lung cancer is a type of cancer that originates in the lungs. It is the leading cause of cancer-related death worldwide. Oncology is the branch of medicine that deals with the diagnosis, treatment, and prevention of cancer. Lung cancer is one of the most common types of cancer treated by oncologists. Treatment options for lung cancer include surgery, chemotherapy, radiation therapy, and targeted therapy.
The lung cancer market is a rapidly growing segment of the oncology market. It is driven by the increasing prevalence of lung cancer, advances in treatment options, and the increasing availability of targeted therapies. The market is expected to continue to grow in the coming years due to the increasing demand for better treatments and the development of new therapies.
Some companies in the lung cancer market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, and Roche. Show Less Read more